Our six research programmes are contained within three Clusters:
1. Immune tolerance
2. Immunotherapy
3. Inherited disease


Cluster 1:

Immune tolerance

Immune regulation

Our goal is to better understand immune regulation at a cellular and molecular level, apply this knowledge to clinical conditions, and develop strategies to correct defective regulation with new biological therapies.


Cluster 1:

Immune tolerance

Bioengineered tissue transplantation

We study the nature of immune responses in liver and renal transplant patients. We also study immune stimulation by synthetic biomaterials, engineered tissues and therapeutic genes, with the aim to develop tolerance-inducing interventions to prevent immune attack and rejection.


Cluster 2:

Immunotherapy

Immunotherapy of cancer

We research the mechanisms of cancer immunity and cancer-induced tolerance in patients and in experimental models. Genetic engineering of immune cells provides an opportunity to produce cancer-specific T cells that are resistant to cancer-induced immune suppression.


Cluster 2:

Immunotherapy

Viral immunity

Chronic infection with hepatitis B virus, cytomegalovirus and HIV is associated with defective immunity. Uncovering the mechanisms of immune deviation provides a platform for developing immune enhancing therapies to achieve viral immunity in chronic infection.


Cluster 3:

Inherited disease

Immunodeficiency

We focus on improving early diagnosis and therapy of primary immunodeficiency by joining detailed genomic analysis, mechanistic immune function studies and comprehensive clinical data.


Cluster 3:

Inherited disease

Gene therapy of inherited defects

We delivered the first successful gene therapy for haemophilia B using AAV based gene delivery. This work has provided a strong basis to expand this form of gene therapy to other conditions, including haemophilia A and lysosomal storage disease.

Page last modified on 24 jun 15 11:12